Supernus Pharmaceuticals Research and Development Expenses 2011-2024 | SUPN

Supernus Pharmaceuticals research and development expenses from 2011 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
Supernus Pharmaceuticals Annual Research and Development Expenses
(Millions of US $)
2023 $92
2022 $75
2021 $90
2020 $76
2019 $69
2018 $89
2017 $50
2016 $43
2015 $29
2014 $20
2013 $17
2012 $24
2011 $31
2010 $35
Supernus Pharmaceuticals Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30 $29
2024-06-30 $26
2024-03-31 $25
2023-12-31 $23
2023-09-30 $23
2023-06-30 $24
2023-03-31 $21
2022-12-31 $18
2022-09-30 $20
2022-06-30 $16
2022-03-31 $21
2021-12-31 $21
2021-09-30 $20
2021-06-30 $15
2021-03-31 $34
2020-12-31 $18
2020-09-30 $17
2020-06-30 $22
2020-03-31 $19
2019-12-31 $20
2019-09-30 $17
2019-06-30 $17
2019-03-31 $15
2018-12-31 $30
2018-09-30 $20
2018-06-30 $20
2018-03-31 $19
2017-12-31 $16
2017-09-30 $13
2017-06-30 $11
2017-03-31 $10
2016-12-31 $13
2016-09-30 $8
2016-06-30 $11
2016-03-31 $11
2015-12-31 $9
2015-09-30 $9
2015-06-30 $7
2015-03-31 $4
2014-12-31 $6
2014-09-30 $5
2014-06-30 $5
2014-03-31 $4
2013-12-31 $5
2013-09-30 $4
2013-06-30 $4
2013-03-31 $5
2012-12-31 $5
2012-09-30 $8
2012-06-30 $5
2012-03-31 $5
2011-12-31 $8
2011-09-30 $8
2011-06-30 $7
2011-03-31 $7
2010-12-31
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.089B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.384B 6.36
Dr Reddy's Laboratories (RDY) India $12.329B 23.59
BridgeBio Pharma (BBIO) United States $4.629B 0.00
Bausch Health Cos (BHC) Canada $3.358B 2.43
Amphastar Pharmaceuticals (AMPH) United States $2.294B 13.79
Taysha Gene Therapies (TSHA) United States $0.490B 79.67
Personalis (PSNL) United States $0.278B 0.00
Assembly Biosciences (ASMB) United States $0.105B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.004B 0.00
Teligent (TLGT) United States $0.000B 0.00